These findings suggest MALAT1 plays a role in therapy resistance that can be highly context-specific in regard to the type of therapy (cisplatin vs. targeted therapy) or cancer primary site (lung vs. kidney) and support the need to study these functions and mechanisms in physiologically relevant settings. Here, MALAT1 is linked to cancer.